Studies on the Quantification of Mutation Resistance to Specific Drug Therapy in Chronic Myeloid Leukemia patients
Sign Up to like & getrecommendations! Published in 2021 at "Research Journal of Pharmacy and Technology"
DOI: 10.52711/0974-360x.2021.00709
Abstract: Imatinib is a type of protein tyrosine kinase inhibitor which inhibits the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome i.e. the BCR-ABL tyrosine kinase, abnormality in CML patient. The aim of the study… read more here.
Keywords: 12th month; imatinib; resistance; 18th month ... See more keywords